Showing 1 - 20 results of 3,875 for search '(((( i marked decrease ) OR ( via lasso decrease ))) OR ( a marker decrease ))', query time: 0.66s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4

    Evogliptin attenuates the pyroptotic cell death of VSMCs during CER treatment by decreasing the pyroptotic-associated genes and GSDM-D cleavage efficiency <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

    Published 2025
    “…<p>(A) Bar graph showed EVO significantly decreased Lactate dehydrogenase (LDH) release in CER treated P<sub>i</sub>‐induced VSMCs. …”
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11

    Table 5_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx by Jianwei Hong (6918776)

    Published 2025
    “…These findings suggest that S100A9 serves as a common inflammatory marker for both diseases, whereas MYH2 may be regulated by disease-specific mechanisms, highlighting its potential for distinguishing COPD from NAFLD.…”
  12. 12

    Table 1_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx by Jianwei Hong (6918776)

    Published 2025
    “…These findings suggest that S100A9 serves as a common inflammatory marker for both diseases, whereas MYH2 may be regulated by disease-specific mechanisms, highlighting its potential for distinguishing COPD from NAFLD.…”
  13. 13

    Table 4_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx by Jianwei Hong (6918776)

    Published 2025
    “…These findings suggest that S100A9 serves as a common inflammatory marker for both diseases, whereas MYH2 may be regulated by disease-specific mechanisms, highlighting its potential for distinguishing COPD from NAFLD.…”
  14. 14

    Table 3_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx by Jianwei Hong (6918776)

    Published 2025
    “…These findings suggest that S100A9 serves as a common inflammatory marker for both diseases, whereas MYH2 may be regulated by disease-specific mechanisms, highlighting its potential for distinguishing COPD from NAFLD.…”
  15. 15

    Table 6_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx by Jianwei Hong (6918776)

    Published 2025
    “…These findings suggest that S100A9 serves as a common inflammatory marker for both diseases, whereas MYH2 may be regulated by disease-specific mechanisms, highlighting its potential for distinguishing COPD from NAFLD.…”
  16. 16

    Table 2_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx by Jianwei Hong (6918776)

    Published 2025
    “…These findings suggest that S100A9 serves as a common inflammatory marker for both diseases, whereas MYH2 may be regulated by disease-specific mechanisms, highlighting its potential for distinguishing COPD from NAFLD.…”
  17. 17
  18. 18
  19. 19
  20. 20